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QUESTIONS
1. How might nonsteroidal anti-inflammatory drugs inhibit the development of skin cancer?
2. How did the investigators carry out their study?
3. What were the results and conclusions?
4. What are the clinical implications?
Melanoma is the deadliest of the common skin cancers. Unfortunately, 
the incidence of this type of malignancy continues to rise, and treat-
ment options for advanced melanoma remain limited (Federman et 
al., 2009). Therefore, prevention remains the best way to avoid the 
morbidity and mortality associated with melanoma. Recently, follow-
up data from a trial evaluating daily sunscreen use indicated that such 
use reduced the incidence of melanoma (Green et al., 2011); interest-
ingly, however, it was also found that individuals regularly ask what 
else they can do to reduce their risk of melanoma.
Experimental and clinical data suggest the potential of inhibiting 
cyclooxygenase (COX), the rate-limiting enzyme for the production 
of prostaglandins from arachidonic acid. Specifically, the inducible 
enzyme COX-2 is markedly overexpressed at sites of inflammation 
and neoplasia, including melanoma (Minami et al., 2011). Over the 
past several years, observational studies have suggested that regular 
use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce 
melanoma development and progression (Ramirez et al., 2005).
To further evaluate chemoprevention for melanoma, Curiel-Lewandrowski and colleagues (2011, this issue) used 
a case–control design to evaluate the effects of NSAIDs and lipid-lowering statins on the incidence of cutaneous 
melanoma in a population of 400 patients recently diagnosed with melanoma as well as 600 case-matched controls. 
Although the investigators reported no benefit in cutaneous melanoma risk with statin use, they determined that 
long-term use of NSAIDs decreased the likelihood of developing melanoma by nearly 50%. A similar reduction in 
risk was found for the use of aspirin. This work offers insight into other strategies that patients can use to reduce their 
chances of developing melanoma. A better understanding of this association is critical to direct patient care. Through 
the following questions, we examine this paper in greater detail. For brief answers, please refer to the supplementary 
information online <http://www.nature.com/jid/journal/v131/n7/suppinfo/jid2011154s1.html>.
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